Literature DB >> 34473502

An Activity-Based Probe for Cathepsin K Imaging with Excellent Potency and Selectivity.

Carina Lemke1, Jakub Benýšek2,3, Dominik Brajtenbach1, Christian Breuer1,4, Adéla Jílková2, Martin Horn2, Michal Buša2,5, Lenka Ulrychová2, Annika Illies1, Katharina F Kubatzky6, Ulrike Bartz4, Michael Mareš2, Michael Gütschow1.   

Abstract

The cysteine protease cathepsin K is a target for the treatment of diseases associated with high bone turnover. Cathepsin K is mainly expressed in osteoclasts and responsible for the destruction of the proteinaceous components of the bone matrix. We designed various fluorescent activity-based probes (ABPs) and their precursors that bind to and inactivate cathepsin K. ABP 25 exhibited extraordinary potency (kinac/Ki = 35,300 M-1s-1) and selectivity for human cathepsin K. Crystal structures of cathepsin K in complex with ABP 25 and its nonfluorescent precursor 21 were determined to characterize the binding mode of this new type of acrylamide-based Michael acceptor with the particular orientation of the dibenzylamine moiety to the primed subsite region. The cyanine-5 containing probe 25 allowed for sensitive detection of cathepsin K, selective visualization in complex proteomes, and live cell imaging of a human osteosarcoma cell line, underlining its applicability in a pathophysiological environment.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34473502     DOI: 10.1021/acs.jmedchem.1c01178

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

Review 1.  Activity-Based Probes for Proteases Pave the Way to Theranostic Applications.

Authors:  Georgia Sotiropoulou; Eleni Zingkou; Evangelos Bisyris; Georgios Pampalakis
Journal:  Pharmaceutics       Date:  2022-04-30       Impact factor: 6.525

2.  Highly potent inhibitors of cathepsin K with a differently positioned cyanohydrazide warhead: structural analysis of binding mode to mature and zymogen-like enzymes.

Authors:  Jakub Benýšek; Michal Buša; Petra Rubešová; Jindřich Fanfrlík; Martin Lepšík; Jiří Brynda; Zuzana Matoušková; Ulrike Bartz; Martin Horn; Michael Gütschow; Michael Mareš
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.